Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Biology and Signal Transduction

Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target

Yang Liu and David J. Kwiatkowski
Yang Liu
Translational Medicine Division, Department of Medicine, Brigham and Women Hospital, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Kwiatkowski
Translational Medicine Division, Department of Medicine, Brigham and Women Hospital, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dk@rics.bwh.harvard.edu
DOI: 10.1158/1535-7163.MCT-14-0622-T Published January 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    CDKN1A mutations in bladder cancer. A, diagram of the structure of the CDKN1A encoded protein p21 with mutations identified by the TCGA in bladder cancer (19) indicated above. Red circles, indel frame-shift mutations; yellow circles, nonsense mutations; and green circles, missense mutations. Mutations identified in bladder cancer cell lines are shown below. B, comutation plot for TP53 and CDKN1A mutations in the TCGA bladder cancer dataset (from http://www.cbioportal.org; ref. 19). It can be seen that eight (44%) CDKN1A mutations occur in cancers with TP53 mutations, and 10 (56%) occur in cancers without TP53 mutations. C, p21 expression in 14 bladder cancer cell lines assessed by immunoblotting. Actin was used as loading control; *, p21-mutated or -deficient cell lines. Note that some cell lines are loaded twice, as controls. D, activation of Chk1 by phosphorylation at S345, and induction of p21 by treatment with gemcitabine at 500 nmol/L for 12 hours. Note that cell lines TCCSUP and HCV29 are wild-type for each of TP53/CDKN1A; J82 is TP53 mutant and CDKN1A wild-type; 97-1 is TP53 wild-type and p21-deficient; whereas 647V and RT-112 are mutant for each of TP53/CDKN1A. E, p21 induction and pChk1-S345 and pChk1-S317 levels are increased by gemcitabine treatment in the TP53/CDKN1A wild-type cell line HCV29.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Synergistic effect of combined Chk1 inhibition and gemcitabine treatment in bladder cancer cell lines. A, cell viability curves are shown for a fixed dose of PF-477736 (PF, 500 nmol/L) and variable dose of gemcitabine (Gem, x-axis). Cell counts were assessed by CellTiter-Glo assay. Note that the reduction in cell viability is much higher for the CDKN1A-mutant cell lines 647V and RT-112 (both also mutant for TP53) and 97-1. B, cell viability curves are shown for various doses of PF-477736 (PF, top) and AZD7762 (AZD, bottom; 0, 50, 100, 200, and 400 nmol/L for each), and variable doses of gemcitabine (Gem, 0–50 nmol/L, x-axis). Cell viability was determined after 2 days incubation using CellTiter-Glo.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Cell-cycle kinetics and apoptosis of bladder cancer cell lines treated with gemcitabine and Chk1 inhibitor. A, effects of no treatment, gemcitabine alone (200 nmol/L × 1 hour), and gemcitabine followed by PF-477736 (500 nmol/L × 23 hours) on cell-cycle distribution of HCV29, J82, 97-1, 647V, and RT-112 cell lines measured 23 hours following cytotoxic treatment. Cell-cycle distribution was assessed by PI-DNA staining and FACS assay. B, cell-cycle distribution in gemcitabine-treated bladder cancer cells (as in A). Histograms, for cell-cycle distribution, as assessed by PI-DNA staining and FACS assay. C, bladder cancer cell lines were exposed to gemcitabine or PF477736, as well as the combination of these two agents for 18 hours. Immunoblot analysis was used to examine levels of PARP1, p-Chk1-345, p-γH2A.X-S139, and β-actin. Note major increase in cleaved PARP1 (PARP1-CL) and p-γH2A.X-S139 in the 647V and RT-112 cell lines. PARP1-FL is full-length PARP1.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    p21 expression is critical to the response to combination treatment in p21-deficient bladder cancer cell lines. A–C, left, cell viability curves for 97-1, 647V, and RT-112 cell lines expressing doxycycline (Doxy)-inducible p21. Cell number was assessed by CellTiter-Glo after treatment with or without doxycycline to induce p21Cip1 expression, and treatment with 500 nmol/L PF-477736 and variable doses of gemcitabine. Right, immunoblot analysis of these treated cells. Note the induction of p21 and reduction in cleaved PARP-1 and p-γH2A.X expression in cells exposed to doxycycline.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Chk1 inhibition synergizes with gemcitabine to reduce bladder cancer cell growth in a xenograft model. A, RT-112 (5 × 106) cells were injected into the flanks of CB17/SCID mice. After the subcutaneous tumors reached a size of 10 cm3, mice were randomized to treatment with vehicle, gemcitabine (50 mg/kg) every 3 days, PF-477736 (15 mg/kg) every 3 days, or both drugs every 3 days at the same dose. Mean ± SD of tumor volume is shown. B and C, tumor weight (B) and tumor images (C) 7 weeks after mice were injected s.c. with the RT-112 cell line, and treated with gemcitabine or PF-477736, or the combination, as in A; mean ± SD. D, weights of mice undergoing treatment with vehicle, gemcitabine, PF-477736, or the combination. Mean ± SD of the normalized weight from the time of treatment initiation is shown.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (1)
January 2015
Volume 14, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
Yang Liu and David J. Kwiatkowski
Mol Cancer Ther January 1 2015 (14) (1) 174-182; DOI: 10.1158/1535-7163.MCT-14-0622-T

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
Yang Liu and David J. Kwiatkowski
Mol Cancer Ther January 1 2015 (14) (1) 174-182; DOI: 10.1158/1535-7163.MCT-14-0622-T
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Ormeloxifene and Prostate Cancer
  • Proinflammatory Cytokines and Drug Resistance
  • Decitabine and the MUC1-C Inhibitor Synergize in CTCL
Show more Cancer Biology and Signal Transduction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement